Gold Price Hits Two-Month High as Investors Await US Inflation Data 
U.S. Stock Futures Flat Ahead of July CPI Data 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Yen Stabilizes After Intervention Slide as Australian Dollar Hits Eight-Week High 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Australia Sets New Minimum Pay, Insurance Rules for Gig Workers 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
